This information is current as of February 9, 2011. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
AMG 139 is a fully human monoclonal antibody. It is being investigated as a treatment for a variety of inflammatory disorders.
AMG 145 is a fully human monoclonal antibody to Proprotein Convertase Subtilisin/Kexin Type 9 ("PCSK9"), a negative regulator of LDLR. AMG 145 is being investigated for the treatment of hypercholesterolemia.
AMG 151 is an orally-administered small molecule glucokinase activator. It reduces glucose levels via a dual mechanism of action - working in both the pancreas and the liver. It is being investigated as a treatment of type 2 diabetes. Amgen licensed this molecule from Array BioPharma Inc. in 2009.
AMG 157 is a fully human monoclonal antibody that blocks the interaction of TSLP with TSLPR. AMG 157 is being investigated for its potential as a treatment for asthma.
AMG 167 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that inhibits bone formation. AMG 167 is being developed in collaboration with UCB for bone-related conditions.
AMG 181 is a fully human monoclonal antibody. It is being investigated for the treatment of ulcerative colitis.
AMG 191 is a humanized anti-c-Kit monoclonal antibody that inhibits the binding of Stem Cell Factor ("SCF") to c-Kit. Inhibition of SCF binding may have potential therapeutic benefit in a variety of inflammatory diseases.
AMG 208 is a small molecule inhibitor of c-Met that inhibits both ligand-dependent and ligand-independent c-Met activation. It is being investigated as a cancer treatment.
AMG 221 is an orally-administered small molecule antagonist of 11-beta hydroxysteroid dehydrogenase type 1 ("11ß-HSD1"), an enzyme associated with conversion of cortisone to cortisol in the liver and adipose tissue. It may have utility in a variety of metabolic and other disorders.
AMG 319 is an orally-administered small molecule inhibitor of PI3 Kinase δ. It is being investigated as a cancer treatment.
AMG 337 is a selective inhibitor of c-Met, which inhibits multiple mechanisms of c-Met activation. It is being investigated as a cancer treatment.
Systemic lupus erythematosus
AMG 557 is a fully human monoclonal antibody that binds to B7 related protein ("B7RP-1"). It is being investigated for its utility in autoimmune diseases such as systemic lupus erythematosus.
AMG 745 is a peptibody that inhibits myostatin. It is being investigated for its utility to inhibit muscle loss associated with a variety of diseases and conditions.
AMG 747 is a selective small molecule central glycine transporter type-1 ("GlyT-1") inhibitor. It is being investigated as treatment for the cognitive deficits associated with schizophrenia.
AMG 761 is a humanized monoclonal antibody targeted to CCR4 positive T-cells. AMG 761 binding leads to depletion of CCR4 positive T-cells. AMG 761 is being investigated as a therapy for asthma. Amgen licensed this molecule from Kyowa Hakko Kirin Co., Ltd. in 2008.
AMG 780 is a fully human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Systemic lupus erythematosus
AMG 811 is a fully human monoclonal antibody that binds to interferon gamma, a widely active pro-inflammatory cytokine. It is being investigated as a treatment for systemic lupus erythematosus.
AMG 820 is a fully human monoclonal antibody that targets c-fms and decreases tumor associated macrophage ("TAM") function. It is being investigated as a cancer treatment.
AMG 888 is a fully human monoclonal antibody that inhibits human epidermal growth factor receptor 3 ("HER3") oncogenic signaling. AMG 888 is being investigated as a cancer treatment. Amgen is developing this product in collaboration with Daiichi Sankyo.
AMG 900 is an orally-administered small molecule inhibitor of Aurora kinases A, B, and C. It is being investigated as a cancer treatment.
Dulanermin is a recombinant human protein that targets death receptors 4 and 5 ("DR4" and "DR5") and induces apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment. We are developing this molecule in collaboration with Genentech, a member of the Roche Group.
AMG 386 is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Bone-related conditions, including postmenopausal osteoporosis and fracture healing
AMG 785 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that inhibits bone formation. AMG 785 (also known as CDP7851) is being developed in collaboration with UCB for bone-related conditions, including postmenopausal osteoporosis and fracture healing.
AMG 827 is a fully human monoclonal antibody that binds to and blocks signaling via the interleukin-17 receptor. It is being investigated as a treatment for a variety of inflammatory disorders.
AMG 853 is an orally-administered small molecule antagonist of the CRTH2 and D-prostanoid receptors of prostaglandin D2. It is being investigated as a treatment for asthma.
Conatumumab is a fully human monoclonal antibody agonist that targets death receptor 5 and induces apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment.
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
Ganitumab (AMG 479) is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a cancer treatment.
Motesanib is an orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors and stem cell factor receptor. It is being investigated as a cancer treatment. We are developing this product in collaboration with Takeda/Millennium Pharmaceuticals.
Chemotherapy-induced thrombocytopenia
Nplate® is a peptibody agonist of the thrombopoietin (TPO) receptor.
Myelodysplastic syndromes
Nplate® is a peptibody agonist of the thrombopoietin (TPO) receptor.
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being investigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collaboration with Cytokinetics, Inc. ("Cytokinetics").
Rilotumumab (AMG 102) is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter factor. It is being investigated as a cancer treatment.
Sensipar®/Mimpara® is an orally-administered small molecule that lowers parathyroid hormone ("PTH") levels in blood by signaling through the calcium-sensing receptor in parathyroid tissue to inhibit PTH secretion. It also lowers blood calcium and phosphorous levels.
Locally advanced head and neck cancer
Vectibix® is a monoclonal antibody antagonist of the epidermal growth factor receptor ("EGFr") pathway. It is being investigated as a cancer treatment.
AMG 386 is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Aranesp® is a recombinant human protein agonist of the erythropoietin receptor.
Ganitumab (AMG 479) is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a cancer treatment.
First-line non-small cell lung cancer
Motesanib is an orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors and stem cell factor receptor. It is being investigated as a cancer treatment. We are developing this product in collaboration with Takeda/Millennium Pharmaceuticals.
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
Cardiovascular disease in patients with secondary hyperparathyroidism and chronic kidney disease undergoing maintenance dialysis
Sensipar®/Mimpara® is an orally-administered small molecule that lowers parathyroid hormone ("PTH") levels in blood by signaling through the calcium-sensing receptor in parathyroid tissue to inhibit PTH secretion. It also lowers blood calcium and phosphorous levels.
First- and second-line colorectal cancer
Vectibix® is a monoclonal antibody antagonist of the epidermal growth factor receptor ("EGFr") pathway. It is being investigated as a cancer treatment.
Prevention of bone metastases in breast cancer
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
Prevention of bone metastases in prostate cancer
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
Added OncoVEXGM-CSF (talimogene laherparepvec), an oncolytic vaccine for the treatment
of metastatic melanoma and head and neck cancer. Amgen acquired
OncoVEX as part of its acquisition of BioVex Group, Inc., which
closed March 4, 2011.
*Update to this phase 3 program occurred after February 9, 2011
